- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc stock price live, this page displays NASDAQ TVTX stock exchange data. View the TVTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Travere Therapeutics Inc real time stock price chart below.
What Is the Travere Therapeutics Inc Stock Price Today?
The Travere Therapeutics Inc stock price today is 65.71.
What Is the Stock Symbol for Travere Therapeutics Inc?
The stock symbol for Travere Therapeutics Inc is "TVTX."
What Stock Exchange Does Travere Therapeutics Inc Trade On?
Travere Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Travere Therapeutics Inc a Good Stock to Buy?
Determining whether Travere Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TVTX quote. (ISIN: US89422G1076)
What Is the Travere Therapeutics Inc Stock Price Today?
The Travere Therapeutics Inc stock price today is 65.71.
What Is the Stock Symbol for Travere Therapeutics Inc?
The stock symbol for Travere Therapeutics Inc is "TVTX."
What Stock Exchange Does Travere Therapeutics Inc Trade On?
Travere Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Travere Therapeutics Inc a Good Stock to Buy?
Determining whether Travere Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TVTX quote. (ISIN: US89422G1076)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.50
66.38
52 wk Range
17.05
66.38
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.5066.38
52 wk Range
17.0566.38
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TVTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
74.14
Upside
+12.83%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
Retrophin I receives Investment Bank Analyst Rating Update- Investing.com
Pro
Retrophin I receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Retrophin I receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
- Retrophin I receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 74.14
(+12.83% Upside)
Travere Therapeutics Inc SWOT Analysis
Filspari's Triumph | Explore Travere's breakthrough with Filspari's full approval for IgAN treatment, potentially revolutionizing the rare kidney disease market |
Financial Crossroads | Delve into Travere's financial landscape: impressive revenue growth amid negative margins, with analyst targets ranging from $12 to $20 |
Pipeline Potential | Uncover Travere's strategic moves beyond Filspari, including FSGS treatments and potential REMS modifications to expand market reach |
Market Dynamics | Learn how industry trends and competitive landscape shape Travere's future, from KDIGO guideline updates to growing interest in renal treatments |
Travere Therapeutics Inc Earnings Call Summary for Q2/2026
- Q2 revenue hit $169.6M, beating consensus of $160.7M; FILSPARI sales surged 96% YoY to $141.1M on strong IgA nephropathy and new FSGS demand.
- Shares jumped 12% after-hours to $62.78, surpassing 52-week high; stock gained 14.2% from prior close on exceptional quarter results.
- FSGS launch exceeded early IgA nephropathy uptake; management reaffirmed $3B+ peak sales target for FILSPARI across both indications combined.
- Company refinanced debt with $525M convertible notes due 2032; ended quarter with $489.2M cash and securities despite $40M inducement expense.
- Gross-net discounts expected mid-20% range for 2026; Phase III pegtibatinase results due H2 2027, civorebrutinib U.S. IND planned for pipeline expansion.
Last Updated: 2026-08-04, 05:40 p/m
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
-0.10 / -0.08
Revenue / Forecast
169.58M / 160.66M
Compare TVTX to Peers and Sector
Metrics to compare | TVTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTVTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −91.5x | −2.5x | −0.3x | |
PEG Ratio | −1.18 | −0.06 | 0.00 | |
Price/Book | 252.6x | 5.2x | 2.6x | |
Price / LTM Sales | 10.5x | 6.3x | 3.1x | |
Upside (Analyst Target) | 16.4% | 52.9% | 47.6% | |
Fair Value Upside | Unlock | −7.3% | 5.6% | Unlock |
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Travere Therapeutics (TVTX) Stock Price Today?
The Travere Therapeutics stock price today is 65.71 USD.
What Stock Exchange Does Travere Therapeutics Trade On?
Travere Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Travere Therapeutics?
The stock symbol for Travere Therapeutics is "TVTX."
What Is the Travere Therapeutics Market Cap?
As of today, Travere Therapeutics market cap is 6.08B USD.
What Is Travere Therapeutics's Earnings Per Share (TTM)?
The Travere Therapeutics EPS (TTM) is -0.74.
When Is the Next Travere Therapeutics Earnings Date?
Travere Therapeutics will release its next earnings report on Oct 22, 2026.
From a Technical Analysis Perspective, Is TVTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Travere Therapeutics Stock Split?
Travere Therapeutics has split 0 times.
How Many Employees Does Travere Therapeutics Have?
Travere Therapeutics has 497 employees.
What is the current trading status of Travere Therapeutics (TVTX)?
As of Aug 22, 2026, Travere Therapeutics (TVTX) is trading at a price of 65.71 USD, with a previous close of 64.46 USD. The stock has fluctuated within a day range of 64.50 USD to 66.38 USD, while its 52-week range spans from 17.05 USD to 66.38 USD.
What Is Travere Therapeutics (TVTX) Price Target According to Analysts?
The average 12-month price target for Travere Therapeutics is 74.14 USD, with a high estimate of 90 USD and a low estimate of 62 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +12.83% Upside potential.
What Is the TVTX Premarket Price?
TVTX's last pre-market stock price is 65.10 USD. The pre-market share volume is 2,660.00, and the stock has decreased by 0.64, or 0.99%.
What Is the TVTX After Hours Price?
TVTX's last after hours stock price is 65.47 USD, the stock has decreased by -0.24, or -0.37%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.